Tech Company Financing Transactions
Chroma Medicine Funding Round
Chroma Medicine, based in Cambridge, secured $135 million from GV, Alexandria Venture Investments and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
3/1/2023
Transaction Type
Venture Equity
Amount
$135,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to progress its single-dose epigenetic editing therapies and support expansion of novel genetic medicine platform designed to enable precise gene regulation while preserving genomic integrity.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1400 One Kendall Sq. 14-403
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature's innate mechanism for gene regulation, to revolutionize treatment of genetically driven disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Catherine Stehman-Breen
Chief Financial Officer
Brett Kaplan
President
Vic Myer
VP - Bus. Development
Noah Goodman
VP - Finance
Laura Wahlberg
VP - General Counsel
Elinor Shin
VP - Operations
Cecilia Fernandez
VP - R & D
Aron Jaffe
Browse more venture capital transactions:
Prev: 3/1/2023: TandemAI venture capital transaction
Next: 3/1/2023: Mammoth venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs